Why the study?
Do different atrioventricular delays during AV sequential pacing affect plasma ANP and cGMP levels in relation to left ventricular performance in patients with DDD pacemakers?
Do different atrioventricular delays during AV sequential pacing affect plasma ANP and cGMP levels in relation to left ventricular performance in patients with DDD pacemakers?
In patients with DDD pacemakers, plasma ANP and cGMP levels are minimized at the optimal atrioventricular delay that maximizes left ventricular performance.
No takes yet. Share an insight, caveat, or question.
ANP/cGMP may mark optimal AVD in DDD pacing; hypothesis-generating for biomarker-guided programming in prospective trials.
Surdacki et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: